晚期非小细胞肺癌治疗的新趋势  

New trends of advanced non-small cell lung cancer therapy

作　　者：石远凯[1] 郏博[1] 

机构地区：[1]北京协和医学院中国医学科学院肿瘤医院内科,北京100021

出　　处：《中国新药杂志》2012年第17期1985-1991,共7页Chinese Journal of New Drugs

基　　金：国家重大新药创制科技重大专项(2012ZX09303012);卫生部医药卫生科技发展基金(WKJ2007-3-001);国家高技术研究发展计划(863计划)项目(2011AA02A110);中央保健委员会办公室资助课题(B2009B124)

摘　　要：当今肺癌研究的热点是以与肿瘤发生、发展相关的驱动基因为靶点,研发新的药物,进行有针对性的个体化分子靶向治疗,从而改善患者预后。靶向药物、新型化疗药物、抗血管新生药物以及治疗性疫苗等各种治疗手段在晚期非小细胞肺癌(NSCLC)患者的治疗中均取得了显著的进展。其中表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)对于EGFR突变阳性NSCLC患者无论在一线、维持还是二线治疗中疗效均得到肯定;替吉奥胶囊有望成为晚期NSCLC一线、二线治疗新的选择;克唑替尼是棘皮动物微管结合蛋白4与间变淋巴瘤激酶融合基因(EML4-ALK)阳性患者治疗的新标准;抗血管新生药物在NSCLC的治疗疗效得到了进一步证实;EGF疫苗在晚期NSCLC治疗中的结果值得期待。这些成果将会改变目前晚期NSCLC的治疗策略,而基于患者临床特点及分子分型的个体化治疗将成为晚期非小细胞肺癌治疗的新趋势。Developing new molecular targeted drugs according to driver genes that are associated with tumor genesis and development has become the focus in lung cancer researches. Significant progress has been achieved in multiple therapy methods such as targeted agents, novel chemotherapeutic drugs, angiogenesis inhibitors and therapeutic vaccines. Epidermal growth factor receptor tyrosine kinase inhibition （EGFR-TKI） is associated with better survival compared with traditional chemotherapy for NSCLC patients. S-1 will be a new option for advanced NSCLC patients, and crizotinib has become the standard therapy for EML4-ALK positive NSCLC patients. Angiogenesis inhibitors and therapeutic vaccines have been developed rapidly. These results will change the current therapy strategy for NSCLC patients, and individualized therapy according to clinical characteristic and molecular subtype will be the new trend.

关 键 词：非小细胞肺癌 肿瘤标记生物学 药物疗法 预测 

分 类 号：R979.1[医药卫生—药品]